An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial
- PMID: 39875685
- DOI: 10.1038/s41591-024-03351-6
An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial
Abstract
Effective, scalable dementia prevention interventions are needed to address modifiable risk factors given global burden of dementia and challenges in developing disease-modifying treatments. A single-blind randomized controlled trial assessed an online multidomain lifestyle intervention to prevent cognitive decline over 3 years. Participants were dementia-free community-dwelling Australians aged 55-77 years with modifiable dementia risk factors. Eligible participants (n = 6,104, 64% female) were randomized 1:1 to a personalized schedule of online coaching in two to four modules (targeting physical activity, nutrition, cognitive activity and depression or anxiety) or a control group that received module-eligible information only. At 3 years, the mean change in a global cognitive composite, the primary outcome, was met. The mean changes in z scores were 0.28 (95% confidence interval (CI): 0.25-0.32) for intervention, 0.10 (95% CI: 0.07-0.13) for control and 0.18 (95% CI: 0.13-0.23, P < 0.001) for the between-group difference. Trial-related adverse events occurred in 19 (0.60%) intervention and 1 (0.03%) control participant. Randomization of this internet-delivered lifestyle intervention tailored to individual dementia risk factors resulted in significantly better cognition in older adults over 3 years. This intervention is scalable with the potential for population-level rollout that may delay cognitive decline in the general community. Australian New Zealand ClinicalTrials.gov registration: ACTRN12618000851268.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: H.B. has been an advisory board member or consultant to Biogen, Eisai, Eli Lilly, Medicines Australia, Roche, Skin2Neuron Pty, Cranbrook Care and Montefiore Homes. P.S.S. was a member of expert panels for Biogen and Roche in 2020 and 2021. M.V. has a financial interest in and is cofounder and CEO of Skin2Neuron Pty, unrelated to this work. The other authors declare no competing interests.
References
-
- World Health Organization. Global status report on the public health response to dementia. www.who.int/publications/i/item/9789240033245 (2021).
-
- Kivipelto, M., Mangialasche, F. & Ngandu, T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol. 14, 653–666 (2018). - PubMed
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (American Psychiatric Association, 2013).
-
- World Health Organization. International Classification of Diseases, 11th Revision (ICD-11) (World Health Organization, 2019).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous